Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Nov 14, 2014 (12 years ago)

Estriol (Ultra-Micronized)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Cause type: Cross-contamination

Traces of another drug - most often penicillin - got into the product from shared equipment or facilities. Even trace penicillin can trigger a severe allergic reaction in someone who was never meant to receive it. All cross-contamination recalls.

What was recalled

Estriol (Ultra-Micronized) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada

Drug: Estriol

Recalling firm
Attix Pharmaceuticals
Origin
Canada
Initiated by
Voluntary: Firm initiated
FDA recall number
D-657-2015 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Estriol recalls

See all
Class II · Moderate risk

Estriol 1mg/gm

Lack of Processing Controls: Insanitary conditions observed during recent FDA Inspection

Terminated cGMP deviation Wedgewood Village Pharmacy, LLC D-1186-2022
Class II · Moderate risk

Estriol 1mg/gm

Lack of Processing Controls: Insanitary conditions observed during recent FDA Inspection

Terminated cGMP deviation Wedgewood Village Pharmacy, LLC D-1185-2022
Class II · Moderate risk

Estriol 8 mg Capsule

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1421-2020
Class II · Moderate risk

Estriol 6 mg Capsule

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1420-2020

Other recalls by Attix Pharmaceuticals

All 2014 recalls
Class III · Low risk

Mycophenolate Mofetil

cGMP deviation; manufacturer is Not Registered with the Food and Drug Administration

Terminated cGMP deviation Attix Pharmaceuticals Inc D-1047-2016
Class II · Moderate risk

Zonisamide active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-960-2015
Class II · Moderate risk

Zolmitriptan active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-959-2015
Class II · Moderate risk

Zoledronic Acid active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-958-2015